Bevacizumab for glioblastoma

Overview of attention for article published in Therapeutics and Clinical Risk Management, December 2015

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (83rd percentile)
High Attention Score compared to outputs of the same age and source (83rd percentile)

So far, Altmetric has seen 4 X posts from 4 X users, with an upper bound of 1,314 followers.

Glioblastoma News: Bevacizumab for glioblastoma - Dove Medical Press: Bevacizumab for glioblastomaDove Medical... https://t.co/4OXYFbcK3Q